# US 2026/0062716 A1 · Lipid nanoparticle (lnp) composition or formulation for nucleic acid therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062716 A1
- Document ID: US20260062716A1
- Status: Published application
- Kind: A1
- Application number: 19/106,079
- Filed: 2023-08-22
- Published: 2026-03-05
- Earliest claimed: 2022-08-24
- Assignees: PopVax Private Limited
- Applicants: PopVax Private Limited
- Inventors: Sourav Chattopadhyay
- Web page: https://patentgrep.com/patent/US20260062716A1

## CPC

- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/02: Bacterial antigens
- A61K 39/12: Viral antigens
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates generally to lipid nanoparticle compositions comprising a nucleic acid, an ionizable polymer, a cationic lipid, a phospholipid, a sterol, and a PEG-lipid. Further, the present disclosure relates generally to methods of treating or preventing a disease, comprising administering to a subject in need thereof a lipid nanoparticle composition described herein.

## Claims

### Claim 1

A lipid nanoparticle composition comprising:
a. a nucleic acid,
b. an ionizable polymer,
c. a cationic lipid,
d. a phospholipid,
e. a sterol, and
f. a PEG-lipid.

### Claim 2 (depends on 1)

The lipid nanoparticle composition according to claim 1, wherein the nucleic acid is a DNA, an RNA or combination thereof.

### Claim 3 (depends on 2)

The lipid nanoparticle composition according to claim 2, wherein the RNA is a messenger RNA (mRNA), a non-coding RNA (ncRNA) or combination thereof.

### Claim 4 (depends on 3)

The lipid nanoparticle composition according to claim 3, wherein the non-coding RNA (ncRNA) is long non-coding RNA (lncRNA), micro RNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNA), small nuclear RNA (snRNA), and PIWI-interacting RNA (piRNA), transfer RNA (tRNA) or ribosomal RNA (rRNA) or combination thereof.

### Claim 5

The lipid nanoparticle composition according to any one of the preceding claims, wherein the ionizable polymer is present in an amount from 1 mol percent to 25 mol percent.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The lipid nanoparticle composition according to any one of the preceding claims 1-5, wherein the ionizable polymer comprises a biocompatible polymer.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The lipid nanoparticle composition according to any one of the preceding claims 1-6, wherein the ionizable polymer is a chitosan, a cellulose derivative, a poly-L-lysine, a poly-L-glutamic acid, and/or their derivatives or combination thereof.

### Claim 8 (depends on 7)

The lipid nanoparticle composition according to claim 7, wherein the ionizable polymer is a chitosan, a cellulose derivative, and/or their derivatives or combination thereof.

### Claim 9 (depends on 8)

The lipid nanoparticle composition according to claim 8, wherein the chitosan, chitosan derivatives or combination thereof is present in an amount from 1 mol percent to 25 mol percent.

### Claim 10 (depends on 8)

The lipid nanoparticle composition according to claim 8, wherein the cellulose derivative is present in an amount from 1 mol percent to 25 mol percent.

### Claim 11 (depends on 9)

The lipid nanoparticle composition according to claim 9, wherein the chitosan or its derivatives or combination thereof is present in an amount from 1 mol percent to 25 mol percent, 1 mol percent to 20 mol percent, or 1 mol percent to 15 mol percent.

### Claim 12

The lipid nanoparticle composition according to any one of the preceding claims, wherein the cationic lipid is present in an amount from 25 mol percent to 50 mol percent.

### Claim 13

The lipid nanoparticle composition according to any one of the preceding claims, wherein the cationic lipid is N,N-dioleyl-N,Ndimethylammonium chloride (DODAC); N-(2,3-dioleyloxy)propyl)-N,N,Ntrimethylammonium chloride (DOTMA); N,N-distearyl-N,N-dimethylammonium bromide (DDAB); N-(2,3dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP); 3-(N—(N′,N′dimethylaminoethane)-carbamoyl)cholesterol (DC-Chol), N-(1-(2,3-dioleoyloxy)propyl)N-2-(sperminecarboxamido)ethyl)-N,N-dimethylammoniumtrifluoracetate (DOSPA), dioctadecylamidoglycyl carboxyspermine (DOGS), 1,2-dioleoyl-3-dimethylammonium propane (DODAP), N,N-dimethyl-2,3-dioleoyloxy)propylamine (DODMA), N-(1,2-dimyristyloxyprop-3-yl)-N,N-dimethyl-N-hydroxyethyl ammonium bromide (DMRIE), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA), 3-dimethylamino-2-(cholest-5-en-3-beta-oxybutan-4-oxy)-1-(cis,cis-9,12-oc-tadecadienoxy)propane (Clin-DMA), 2-[5′-(cholest-5-en-3-beta-oxy)-3′-oxapentoxy)-3-dimethyl-1-(cis,cis-9′,12′-octadecadienoxy)propane (CpLin-DMA), 2,3-Dilinoleoyloxy-N,N-dimethylpropylamine (DLin-DAP), 1,2-N,N′-Dilinoleylcarbamyl-3-dimethylaminopropane (DLincarb-DAP), 1,2-Dilinoleoylcarbamyl-3-dimethylaminopropane (DLin-CDAP), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-MC3-DMA), heptadecan-9-yl 8-[2-hydroxyethyl-(6-oxo-6-undecoxyhexyl)amino]octanoate (SM-102), 6-[6-(2-hexyldecanoyloxy)hexyl-(4-hydroxybutyl)amino]hexyl 2-hexyldecanoate (ALC-0315), and nonyl 8-[(8-heptadecan-9-yloxy-8-oxooctyl)-(2-hydroxyethyl)amino]octanoate (SLP-0001).

### Claim 14

The lipid nanoparticle composition according to any one of the preceding claims, wherein the cationic lipid comprises an ionizable lipid.

### Claim 15 (depends on 14)

The lipid nanoparticle composition according to claim 14, wherein the ionizable lipid is present in an amount from 25 mol percent to 50 mol percent.

### Claim 16

The lipid nanoparticle composition according to any one of the preceding claims, wherein the phospholipid is present in an amount from 2 mol percent to about 20 mol percent.

### Claim 17 (depends on 16)

The lipid nanoparticle composition according to claim 16, wherein the phospholipid is 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC), 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine (PMPC), 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (PSPC), 1-stearoyl-2-myristoyl-sn-glycero-3-Phosphocholine (SMPC), 1-Stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (SPPC), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC), 1-stearoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine (SDPC), sphingomyelin, and combination thereof.

### Claim 18

The lipid nanoparticle composition according to any one of the preceding claims, wherein the sterol is present in an amount from 30 mol percent to about 65 mol percent.

### Claim 19

The lipid nanoparticle composition according to any one of the preceding claims, wherein the sterol is cholesterol, sitosterol, fecosterol, ergosterol, campesterol, stigmasterol, 5α-cholestanol, 5β-coprostanol, cholesteryl-(2′-hydroxy)-ethyl ether, cholesteryl-(4′-hydroxy)-butyl ether, 6-ketocholestanol, 5α-cholestane, cholestenone, 5α-cholestanone, 5β-cholestanone, cholesteryl decanoate, or their derivatives.

### Claim 20

The lipid nanoparticle composition according to any one of the preceding claims, wherein the PEG-lipid is present in an amount from 0.2 mol percent to about 2.0 mol percent.

### Claim 21

The lipid nanoparticle composition according to any one of the preceding claims, wherein the PEG-lipid is mPEG-Dimyristoyl glycerol (mPEG-DMG), mPEG-N,N-Ditetradecylacetamide (mPEG-DTA or ALC0159), mPEG-Cholesterol (mPEG-CLS), mPEG-DSPE, mPEG-DMPE, mPEG-DPPE, mPEG-DLPE, mPEG-DOPE, mPEG-DPPC, mPEG-DSPC, 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine with conjugated methoxyl poly(ethylene glycol) (mPEG-DSPE), 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG 2000), or mixtures thereof.

### Claim 22

The lipid nanoparticle composition according to any one of the preceding claims, wherein the nucleic acid encodes an antigenic polypeptide or regulate or module a cellular function.

### Claim 23 (depends on 22)

The lipid nanoparticle composition according claim 22, wherein the antigenic polypeptide is derived from an infectious agent.

### Claim 24 (depends on 23)

The lipid nanoparticle composition according claim 23, wherein the infectious agent is selected from strains of viruses and strains of bacteria.

### Claim 25

The lipid nanoparticle composition according to any one of the preceding claims, wherein the nucleic acid comprise at least one chemical modification.

### Claim 26

A nucleic acid vaccine comprising the lipid nanoparticle composition according to any one of the preceding claims.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

A method of treating or preventing a disease comprising administering to a subject in need thereof the lipid nanoparticle composition according to any one of claims 1-25 or the nucleic acid vaccine according to claim 26.

### Claim 28 (depends on 27)

The method of claim 27, wherein the disease is cancer, an infectious disease or a disease and/or disorder ameliorated by humoral and/or cellular immune response.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

Use of the lipid nanoparticle composition according to any one of the preceding claims 1-25 in the manufacture of a medicament for the treatment of a disease in a subject.

### Claim 30 (depends on 29)

The use of claim 29, wherein the disease is cancer, an infectious disease or a disease and/or disorder ameliorated by humoral and/or cellular immune response.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method of preparing the lipid nanoparticle composition of any one of the preceding claims 1-25 comprising mixing an aqueous phase comprising the nucleic acid and the ionizable polymer, and an organic phase comprising the cationic lipid, the phospholipid, the cholesterol and the PEG-lipid.
